Computational Drug Discovery
All research in Computational Drug Discovery — 2 reports.
Certara is a biosimulation software and regulatory-science services provider whose software is used by 20 global regulatory agencies and helps drug developers shorten R&D and approval pathways through modeling and simulation. Software revenue grew nearly 18% year over year in 2025, but the larger services business saw revenue fall 4% and bookings decline 14% in Q1 2026, while full-year core growth guidance is only 0%–4%. Research rating Watch: the software moat remains intact, but the services drag and restructuring execution still need quarterly proof.
Schrödinger is a physics-based computational drug discovery platform built around FEP+, a gold-standard method, with 19 of the world's top 20 pharma companies as software customers and additional upside from internal and partnered pipelines plus repeat equity monetizations. Its current market value is about $1.1 billion, with roughly $300 million of net cash, while the stock is down 86% from its 2021 peak. Research rating Hold: a real platform with a hard moat and cheap parts, but slower software growth and limited near-term catalysts keep the risk-reward balanced.